ClinicalTrials.gg
CompletedNCT03011034Updated Mar 4, 2025Results posted

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

A Phase 2 interventional study of Talacotuzumab and Daratumumab in Myelodysplastic Syndromes, sponsored by Janssen Research & Development, LLC. Completed at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Myelodysplastic Syndromes by Johnson & Johnson — 1 open to participants now, 1 under way, none of them phase 3. Myelodysplastic Syndromes · Johnson & Johnson.

Enrollment
12th of 17
34 · median 62
Started
2017
the only one that year
Phase 2
8 of 21
none open now
Registered
16th of 21
by date

Among the 21 studies in Myelodysplastic Syndromes by Johnson & Johnson, this one is the 12th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2017, is one of 8 in phase 2, and was the 16th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

1 of the 21 studies in Myelodysplastic Syndromes by Johnson & Johnson is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Myelodysplastic Syndromes by Johnson & Johnson, or all of them as a file.
02

Study summary

The main purpose of the study is to evaluate the efficacy (transfusion independence [TI]) of talacotuzumab (JNJ-56022473) or daratumumab in transfusion-dependent participants with low or intermediate-1 risk Myelodysplastic Syndrome (MDS) whose disease has relapsed during treatment with or is refractory to Erythropoiesis-Stimulating Agent (ESAs).

Read the detailed description

This is a multicenter, randomized (study drug assigned by chance), open-label (participants and researchers are aware of the treatment participants are receiving) study to evaluate the safety and efficacy of talacotuzumab or daratumumab. Approximately 60 participants (30 to receive talacotuzumab and 30 to receive daratumumab) will be enrolled and then assigned randomly on a 1:1 basis to receive either talacotuzumab or daratumumab. The study consists of: a Screening Phase of up to 28 days during which participant eligibility will be reviewed and approved by the sponsor prior to randomization, a Treatment Phase that will extend from the first dose on Cycle 1 Day 1 until study drug discontinuation, and a Post-treatment Follow up Phase beginning once the participant discontinues talacotuzumab or daratumumab. Study drugs will continue to be administered until disease progression, lack of response, unacceptable toxicity, withdrawal of consent, or study end. Safety will be monitored throughout the study. The talacotuzumab arm of the study is closed for enrollment.

03

Conditions studied

  • Myelodysplastic Syndromes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Myelodysplastic Syndrome (MDS) according to World Health Organization (WHO) criteria confirmed by bone marrow aspirate and within 12 weeks prior to first dose. A local laboratory report from this diagnostic bone marrow aspirate and biopsy must be approved by the sponsor
  • International Prognostic Scoring System (IPSS) low risk or intermediate-1 risk MDS
  • Red blood cell (RBC) transfusion dependent, 1) Received at least 4 units of RBCs over any 8 consecutive weeks during the 16 weeks prior to randomization, 2) Pretransfusion must have been less than or equal to (\<=)9.0 gram per deciliter (g/dL)
  • Adequate iron stores, defined as transferrin saturation greater than 20 percent (%) and serum ferritin greater than 400 nanogram per Milliliter (ng/mL), measured within the screening period, or adequate iron stores as demonstrated by recent (within 12 weeks prior to first dose) bone marrow examination with iron stain
  • (ECOG) performance status 0, 1 or 2

Exclusion criteria

Exclusion Criteria:

  • Known allergies, , or intolerance to talacotuzumab and daratumumab or their
  • Received any chemotherapy, immunomodulatory or therapy, (greater than [>]30 milligram per day [mg/day] prednisone or equivalent) within 28 days prior to randomization
  • Received other treatments for MDS within 28 days prior to first dose (example [eg], azacitidine, decitabine, lenalidomide, Erythropoiesis-Stimulating Agent (ESA) (8 weeks for long-acting ESAs)
  • History of hematopoietic stem cell transplant
  • Del(5q) karyotype unless treatment with lenalidomide has failed. Failure is defined as either: 1) having received at least 3 months of lenalidomide treatment without RBC transfusion benefit (International Working Group [IWG] 2006); 2) progression or relapse after hematologic improvement with lenalidomide (IWG 2006); 3) discontinuation of lenalidomide due to toxicity; or 4) unable to receive lenalidomide due to a . Source documentation for lenalidomide treatment failure must be verified by the sponsor
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Talacotuzumab

    Participants will receive talacotuzumab 9 milligram per kilogram (mg/kg) intravenously (IV) on Days 1 and 15 for all cycles. Each treatment cycle is of 28 days. The talacotuzumab arm of the study is closed for enrollment.

    Drug: Talacotuzumab

  • Experimental
    Daratumumab

    Participants will receive daratumumab 16 mg/kg IV on Days 1, 8, 15, and 22 for Cycles 1 and 2; on Days 1 and 15 for Cycles 3 to 6; and on Day 1 for all subsequent cycles. Each treatment cycle is of 28 days.

    Drug: Daratumumab

Interventions

  • Talacotuzumab 9 mg/kg will be administered as an IV infusion.

    Also known as: JNJ-56022473

  • Daratumumab 16 mg/kg will be administered as an IV infusion.

    Also known as: JNJ-54767414

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 8 Weeks

    Percentage of participants who achieved RBC TI lasting at least 8 weeks were reported. RBC TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.

    Time frame: Up to 2 years

Secondary outcomes

  1. Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 24 Weeks

    Percentage of participants who achieved RBC TI lasting at least 24 weeks were reported. RBC TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.

    Time frame: Up to 2 years

  2. Time to Transfusion Independence (TI)

    Time to transfusion independence (TI) was defined as time to the start of the TI interval. TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.

    Time frame: Up to 2 years

  3. Duration of Transfusion Independence (TI)

    Duration of TI was reported. TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.

    Time frame: Up to 2 years

  4. Percentage of Participants Who Met IWG Criteria for Transfusion Reduction

    Percentage of participants who met IWG criteria for transfusion reduction were reported. IWG criteria for transfusion reduction: at least 4 units reduction in RBC transfusions in the best 8-week interval. The best 8-week interval was a post-baseline 8-week interval where the participant had the fewest post-baseline RBC transfusion units.

    Time frame: Up to 2 years

  5. Percentage of Participants With at Least One Dose of Myeloid Growth Factors Usage

    Percentage of participants with Myeloid Growth Factors (MGF) usage (who had used at least 1 dose of MGF) were reported.

    Time frame: Up to 2 years

  6. Percentage of Participants With Hematologic Improvement (HI) Per IWG 2006 by Investigator Assessment

    Percentage of participants with HI per International Working Group (IWG) 2006 by investigator assessment were reported. Response criteria per IWG 2006 for HI: Erythroid response (pretreatment, less than \[\<\]11 gram per deciliter \[g/dL\]) - hemoglobin increase by greater than or equal to (\>=)1.5 g/dL, relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 weeks compared with the pretreatment transfusion number in the previous 8 weeks. Only RBC transfusions given for a Hb of \<=9 g/dL pretreatment counted in the RBC transfusion response evaluation; Platelet response (pretreatment, \<100\*10\^9/L) - absolute increase of \>=30\*10\^9/L for participants starting with \>20\*10\^9/L platelets. Increase from \<20\*10\^9/L to \>20\*10\^9/L and by at least 100 percent (%); Neutrophil response (pretreatment, \<1\*10\^9/L) - at least 100% increase and an absolute increase \>0.5\*10\^9/L.

    Time frame: Up to 2 years

  7. Percentage of Participants With Complete Remission (CR) and Marrow CR

    Percentage of participants with CR and marrow CR were reported. CR per International Working Group (IWG) 2006 Response criteria: Bone marrow - less than or equal to (\<=)5% myeloblasts with normal maturation of all cell lines, persistent dysplasia noted; Peripheral blood - hemoglobin \>=11 g/dL; platelets \>=100\*10\^9/L; neutrophils \>=1.0\*10\^9/L; blasts, 0%. Marrow CR: Bone marrow - \<=5% myeloblasts and decrease by \>=50% over pretreatment; Peripheral blood - if HI responses, they were noted in addition to marrow CR.

    Time frame: Up to 2 years

  8. Percentage of Participants With Partial Remission (PR)

    Percentage of participants with PR were reported. PR per International Working Group (IWG) 2006 Response criteria: All CR criteria if abnormal before treatment except: Bone marrow blasts decreased by \>=50% over pretreatment but still \>5%, cellularity and morphology not relevant.

    Time frame: Up to 2 years

  9. Percentage of Participants With Cytogenetic Response

    Percentage of participants with cytogenetic response were reported. Cytogenetic response per International Working Group (IWG) 2006 Response criteria: Complete - disappearance of the chromosomal abnormality without appearance of new ones; Partial - at least 50% reduction of the chromosomal abnormality.

    Time frame: Up to 2 years

  10. Overall Survival

    The overall survival was defined as the time from the date of first dose of study drug to date of death from any cause. Median overall survival was estimated by using the Kaplan-Meier method.

    Time frame: Up to 2 years

  11. Time to Progression to Acute Myeloid Leukemia (AML)

    Time to progression to acute myeloid leukemia was reported. Disease progression as per IWG response criteria: For participants with: \<5% blasts: \>=50% increase in blasts to \>5% blasts; 5%-10% blasts: \>=50% increase to \>10% blasts; 10%-20% blasts: \>=50% increase to \>20% blasts; 20%-30% blasts: \>=50% increase to \>30% blasts. Any of the following: \>=50% decrement from maximum remission/response in granulocytes or platelets; reduction in hemoglobin by \>=2 g/dL; transfusion dependence.

    Time frame: Up to 2 years

07

Results

Posted Mar 13, 2020
Limitations and caveats
Study objectives were not pursued in talacotuzumab arm; enrollment in this arm was stopped due to a serious infusion-related reaction after first dose in first participant assigned to talacotuzumab.

Participant flow

Out of 34 enrolled participants, 33 participants received daratumumab and 1 participant received talacotuzumab.

Participant flow — Overall Study
MilestoneTalacotuzumabDaratumumab
Started133
Completed033
Not completed10
Withdrew: Adverse event10

Outcome measures

PrimaryPercentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 8 Weeks

Percentage of participants who achieved RBC TI lasting at least 8 weeks were reported. RBC TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 8 Weeks
Percentage of participantsTalacotuzumabDaratumumab
Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 8 Weeks06.1 (0.7 to 20.2)
SecondaryPercentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 24 Weeks

Percentage of participants who achieved RBC TI lasting at least 24 weeks were reported. RBC TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 24 Weeks
Percentage of participantsTalacotuzumabDaratumumab
Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 24 Weeks03.0 (0.1 to 15.8)
SecondaryTime to Transfusion Independence (TI)

Time to transfusion independence (TI) was defined as time to the start of the TI interval. TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.

Time frame:
Up to 2 years
Reported as:
Number · Weeks
Time to Transfusion Independence (TI)
WeeksTalacotuzumabDaratumumab
Participant 1—4
Participant 2—5
Participant 3NA—
SecondaryDuration of Transfusion Independence (TI)

Duration of TI was reported. TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.

Time frame:
Up to 2 years
Reported as:
Number · Weeks
Duration of Transfusion Independence (TI)
WeeksTalacotuzumabDaratumumab
Participant 1—16
Participant 2—65
Participant 3NA—
SecondaryPercentage of Participants Who Met IWG Criteria for Transfusion Reduction

Percentage of participants who met IWG criteria for transfusion reduction were reported. IWG criteria for transfusion reduction: at least 4 units reduction in RBC transfusions in the best 8-week interval. The best 8-week interval was a post-baseline 8-week interval where the participant had the fewest post-baseline RBC transfusion units.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of participants
Percentage of Participants Who Met IWG Criteria for Transfusion Reduction
Percentage of participantsTalacotuzumabDaratumumab
Percentage of Participants Who Met IWG Criteria for Transfusion Reduction054.5
SecondaryPercentage of Participants With at Least One Dose of Myeloid Growth Factors Usage

Percentage of participants with Myeloid Growth Factors (MGF) usage (who had used at least 1 dose of MGF) were reported.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Dose of Myeloid Growth Factors Usage
Percentage of participantsTalacotuzumabDaratumumab
Percentage of Participants With at Least One Dose of Myeloid Growth Factors Usage09.1
SecondaryPercentage of Participants With Hematologic Improvement (HI) Per IWG 2006 by Investigator Assessment

Percentage of participants with HI per International Working Group (IWG) 2006 by investigator assessment were reported. Response criteria per IWG 2006 for HI: Erythroid response (pretreatment, less than \[\<\]11 gram per deciliter \[g/dL\]) - hemoglobin increase by greater than or equal to (\>=)1.5 g/dL, relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 weeks compared with the pretreatment transfusion number in the previous 8 weeks. Only RBC transfusions given for a Hb of \<=9 g/dL pretreatment counted in the RBC transfusion response evaluation; Platelet response (pretreatment, \<100\*10\^9/L) - absolute increase of \>=30\*10\^9/L for participants starting with \>20\*10\^9/L platelets. Increase from \<20\*10\^9/L to \>20\*10\^9/L and by at least 100 percent (%); Neutrophil response (pretreatment, \<1\*10\^9/L) - at least 100% increase and an absolute increase \>0.5\*10\^9/L.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Hematologic Improvement (HI) Per IWG 2006 by Investigator Assessment
Percentage of participantsTalacotuzumabDaratumumab
Erythroid Response09.1 (1.9 to 24.3)
Platelet Response00.0 (0.0 to 10.6)
Neutrophil Response00.0 (0.0 to 10.6)
SecondaryPercentage of Participants With Complete Remission (CR) and Marrow CR

Percentage of participants with CR and marrow CR were reported. CR per International Working Group (IWG) 2006 Response criteria: Bone marrow - less than or equal to (\<=)5% myeloblasts with normal maturation of all cell lines, persistent dysplasia noted; Peripheral blood - hemoglobin \>=11 g/dL; platelets \>=100\*10\^9/L; neutrophils \>=1.0\*10\^9/L; blasts, 0%. Marrow CR: Bone marrow - \<=5% myeloblasts and decrease by \>=50% over pretreatment; Peripheral blood - if HI responses, they were noted in addition to marrow CR.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Remission (CR) and Marrow CR
Percentage of participantsTalacotuzumabDaratumumab
Complete Remission (CR)00
Marrow CR03.0
SecondaryPercentage of Participants With Partial Remission (PR)

Percentage of participants with PR were reported. PR per International Working Group (IWG) 2006 Response criteria: All CR criteria if abnormal before treatment except: Bone marrow blasts decreased by \>=50% over pretreatment but still \>5%, cellularity and morphology not relevant.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Partial Remission (PR)
Percentage of participantsTalacotuzumabDaratumumab
Percentage of Participants With Partial Remission (PR)00
SecondaryPercentage of Participants With Cytogenetic Response

Percentage of participants with cytogenetic response were reported. Cytogenetic response per International Working Group (IWG) 2006 Response criteria: Complete - disappearance of the chromosomal abnormality without appearance of new ones; Partial - at least 50% reduction of the chromosomal abnormality.

Time frame:
Up to 2 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Cytogenetic Response
Percentage of participantsTalacotuzumabDaratumumab
Percentage of Participants With Cytogenetic Response00
SecondaryOverall Survival

The overall survival was defined as the time from the date of first dose of study drug to date of death from any cause. Median overall survival was estimated by using the Kaplan-Meier method.

Time frame:
Up to 2 years
Reported as:
Median · Months
Overall Survival
MonthsTalacotuzumabDaratumumab
Overall SurvivalNA (NA to NA)NA (NA to NA)
SecondaryTime to Progression to Acute Myeloid Leukemia (AML)

Time to progression to acute myeloid leukemia was reported. Disease progression as per IWG response criteria: For participants with: \<5% blasts: \>=50% increase in blasts to \>5% blasts; 5%-10% blasts: \>=50% increase to \>10% blasts; 10%-20% blasts: \>=50% increase to \>20% blasts; 20%-30% blasts: \>=50% increase to \>30% blasts. Any of the following: \>=50% decrement from maximum remission/response in granulocytes or platelets; reduction in hemoglobin by \>=2 g/dL; transfusion dependence.

Time frame:
Up to 2 years
Reported as:
Median · Weeks
Time to Progression to Acute Myeloid Leukemia (AML)
WeeksTalacotuzumabDaratumumab
Time to Progression to Acute Myeloid Leukemia (AML)NA (NA to NA)NA (54.7 to NA)

Adverse events

Collected over Up to 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Talacotuzumab0/1 (0%)1/1 (100%)1/1 (100%)
Daratumumab6/33 (18.2%)15/33 (45.5%)33/33 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventTalacotuzumabDaratumumab
Metabolic AcidosisMetabolism and nutrition disorders1/10/33
DyspnoeaRespiratory, thoracic and mediastinal disorders1/10/33
PyrexiaGeneral disorders0/13/33
PneumoniaInfections and infestations0/13/33
Acute Coronary SyndromeCardiac disorders0/11/33
Atrial FibrillationCardiac disorders0/11/33
Cardiac FailureCardiac disorders0/11/33
Cardiac Failure CongestiveCardiac disorders0/11/33
DiarrhoeaGastrointestinal disorders0/11/33
Rectal HaemorrhageGastrointestinal disorders0/11/33
Most frequent other events
Showing 10 of 47
Most frequent other events
EventTalacotuzumabDaratumumab
NauseaGastrointestinal disorders1/13/33
VomitingGastrointestinal disorders1/13/33
Renal ImpairmentRenal and urinary disorders1/10/33
Rhinitis allergicRespiratory, thoracic and mediastinal disorders1/10/33
ThrombocytopeniaBlood and lymphatic system disorders0/19/33
PyrexiaGeneral disorders0/18/33
DiarrhoeaGastrointestinal disorders0/17/33
AnaemiaBlood and lymphatic system disorders0/16/33
NeutropeniaBlood and lymphatic system disorders0/16/33
AstheniaGeneral disorders0/16/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)TalacotuzumabDaratumumabTotal
Mean6771.5 ± 6.8671.4 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)TalacotuzumabDaratumumabTotal
Female088
Male12526
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TalacotuzumabDaratumumabTotal
Hispanic or Latino044
Not Hispanic or Latino12728
Unknown or Not Reported022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TalacotuzumabDaratumumabTotal
Other011
Unknown or Not Reported033
White12930
Region of Enrollment
Region of Enrollment(Participants)TalacotuzumabDaratumumabTotal
BELGIUM167
ITALY033
NETHERLANDS033
RUSSIAN FEDERATION033
SPAIN01010
UNITED STATES088
08

Study locations

21 sites
  • Washington University School Of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Pennsylvania Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • University of Texas, MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • ZNA Stuivenberg
    Antwerp, 2060, Belgium
  • Az Groeninge
    Kortrijk, 8500, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • AZ Turnhout
    Turnhout, 2300, Belgium
  • Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna
    Bologna, 40138, Italy
  • Azienda Ospedaliero Universitaria Careggi
    Firenze, 50134, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Pad. Marcora
    Milano, 20122, Italy
  • Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Haga ziekenhuis
    Den Haag, 2545 CH, Netherlands
  • UMCG
    Groningen, 9713 GZ, Netherlands
  • Erasmus MC
    Rotterdam, 3075 EA, Netherlands
  • City Clinical Hospital # 40
    Moscow, 129301, Russian Federation
  • Nizhniy Novgorod Region Clinical Hospital
    Nizhny Novgorod, 603126, Russian Federation
  • Saint Petersburg City Hospital #15
    Saint-Petersburg, 123182, Russian Federation
  • Hosp Univ Vall D Hebron
    Barcelona, 08035, Spain
  • Hosp. Univ. de La Princesa
    Madrid, 28006, Spain
  • Hosp Clinico Univ de Salamanca
    Salamanca, 37007, Spain
  • Hosp. Univ. I Politecni La Fe
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jan 2019, 23 months.

Results were first posted in Mar 2020, 1 year 1 month after primary completion.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 23 months is below that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2017
First posted
Jan 5, 2017
StartActual
Feb 14, 2017
Primary completionActual
Jan 23, 2019
CompletionActual
Oct 5, 2021
Results first posted
Mar 13, 2020
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03011034
Responsible party
Sponsor
First posted
Jan 5, 2017
Start date
Feb 14, 2017
Primary completion
Jan 23, 2019
Completion
Oct 5, 2021
Results posted
Mar 13, 2020
Last update
Mar 4, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Talacotuzumab · Daratumumab

Start the discussion